Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board

Oct 27, 2010, 09:15 ET from Regenicin, Inc.

NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDST), a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, announced today the appointment of Dr. Gervaise Gerstner to the company's Scientific Advisory Board. Dr. Gerstner is a board-certified dermatologist and Assistant Clinical Professor of Dermatology at Mount Sinai Hospital in New York.

Dr. Gerstner earned her M.D. from Mount Sinai Medical School in New York City and completed a dermatology residency at Mount Sinai Hospital, where she was chosen to serve as Chief Resident of Dermatology. She is an associate member of the American Academy of Dermatology and the American Academy of Dermatologic Surgeons, and is a member of both the Dermatology Foundation and the Skin Cancer Foundation.  

"Dr. Gerstner brings more than ten years of clinical dermatology experience to our board," says Randall McCoy, CEO of Regenicin. "We are certain she will play a pivotal role in guiding the development of new applications, markets and technologies for the treatment of skin."

Dr. Gerstner, who is one of the world's first doctors trained in the highly advanced Fraxel laser, has conducted research on a wide range of topics from chemical peels to melanoma. Her work has been published in leading dermatologic journals and she served as book editor for Clinics in Dermatology. She is also regularly featured in national and regional media including W Magazine, Harper's Bazaar, Allure, Glamour, Self, New York and Real Simple.

"I worked closely with burn patients in medical school and during my residency, and continue to do so in my current practice," says Dr. Gerstner. "I am delighted to be part of a company that is on the cutting-edge of making life-saving technologies available for the treatment chronic burns and wounds."

About Regenicin, Inc.

Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin, Inc.